BUKWANG Corporate Governance Report: Enhanced Shareholder Returns via Share Cancellation and Dividend Increase, Rights Offering and Acquisition for Growth
Consolidated revenue of 200.7B KRW and operating profit of 14.2B KRW in fiscal year 2025, turning profitable YoY.
Raised 146.7B KRW via rights offering (30,210,000 shares) for facility and operating funds with existing shareholders' preemptive rights.
Acquired Korea Union Pharm through a third-party allotment to expand production capacity and business.
Cancelled 2,608,378 treasury shares (approx. 2.64%) and paid a dividend of 125 won per share (50 interim + 75 final).
No change in controlling shareholder (OCI Holdings, 17.11%); minority shareholders hold 67.22%.
Improved governance: majority independent directors, fully independent audit and compensation committees, new ESG committee.
[AI Summary]BUKWANG strengthened shareholder returns through a 2.64% share cancellation and increased dividend (125 won per share), but the 30.2 million share rights offering may pressure the stock in the short term. The acquisition of Korea Union Pharm is positive for long-term growth, but investors should monitor post-merger integration and increased leverage.